| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jalpa A Doshi, Amy R Pettit, Jeffrey J Stoddard, Jacqueline Zummo, Steven C Marcu. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge. Journal of clinical psychopharmacology. vol 35. issue 4. 2016-04-18. PMID:26075492. |
specifically, we examined patients with a recent history of nonadherence and hospitalization for schizophrenia and included both first-generation antipsychotic depot medications (fluphenazine decanoate, haloperidol decanoate) and more recently available second-generation injectables (lai risperidone, paliperidone palmitate). |
2016-04-18 |
2023-08-13 |
Not clear |
| Yen-Feng Lee, Chia-Kuang Tsai, Chih-Sung Lian. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation. Clinical neuropharmacology. vol 38. issue 4. 2016-04-11. PMID:26166241. |
we report a case of a patient with schizophrenia treated with high-dose risperidone, who developed syndrome of inappropriate antidiuretic hormone secretion (siadh) with the only early symptom of tonic-clonic seizures. |
2016-04-11 |
2023-08-13 |
Not clear |
| Yen-Feng Lee, Chia-Kuang Tsai, Chih-Sung Lian. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation. Clinical neuropharmacology. vol 38. issue 4. 2016-04-11. PMID:26166241. |
a 40-year-old woman with schizophrenia was treated with risperidone 2 mg/d. |
2016-04-11 |
2023-08-13 |
Not clear |
| Joseph J Topczewski, Pablo J Cabrera, Noam I Saper, Melanie S Sanfor. Palladium-catalysed transannular C-H functionalization of alicyclic amines. Nature. vol 531. issue 7593. 2016-04-05. PMID:26886789. |
saturated nitrogen-containing heterocycles (alicyclic amines) feature prominently in pharmaceuticals, such as treatments for depression (paroxetine, amitifadine), diabetes (gliclazide), leukaemia (alvocidib), schizophrenia (risperidone, belaperidone), malaria (mefloquine) and nicotine addiction (cytisine, varenicline). |
2016-04-05 |
2023-08-13 |
Not clear |
| Maria Corena-McLeo. Comparative Pharmacology of Risperidone and Paliperidone. Drugs in R&D. vol 15. issue 2. 2016-03-25. PMID:25943458. |
antipsychotics, risperidone, and risperidone's active metabolite, paliperidone (9-hydroxyrisperidone), are related molecules used for the treatment of schizophrenia and related disorders. |
2016-03-25 |
2023-08-13 |
rat |
| Pierre S Chue, Peter D'Hoore, J Michael Ramstac. Sustained drug delivery optimizes long-term treatment of patients with schizophrenia. Acta neuropsychiatrica. vol 16. issue 6. 2016-03-18. PMID:26984545. |
the first antipsychotic to achieve this combination - long-acting risperidone - may thus represent an important advance in the optimization of long-term treatment outcomes in patients with schizophrenia. |
2016-03-18 |
2023-08-13 |
Not clear |
| M Wardenier, C J Slooff, J Arend. Efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia. Acta neuropsychiatrica. vol 12. issue 4. 2016-03-16. PMID:26975433. |
efficacy of risperidone, olanzapine and clozapine in the treatment of therapy resistant schizophrenia. |
2016-03-16 |
2023-08-13 |
Not clear |
| Alan I Green, Mary F Brunette, Ree Dawson, Peter Buckley, Amy E Wallace, Hisham Hafez, Marvin Herz, Meera Narasimhan, Douglas L Noordsy, Christopher O'Keefe, Roger W Sommi, Richard M Steinbook, Marjorie Week. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. The Journal of clinical psychiatry. vol 76. issue 10. 2016-03-14. PMID:26302441. |
long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. |
2016-03-14 |
2023-08-13 |
Not clear |
| Veena Kumari, Ulrich Ettinger, Seoung Eun Lee, Christine Deuschl, Anantha P Anilkumar, Anne Schmechtig, Philip J Corr, Dominic H Ffytche, Steven C R William. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study. Psychopharmacology. vol 232. issue 17. 2016-03-09. PMID:25980483. |
common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fmri study. |
2016-03-09 |
2023-08-13 |
Not clear |
| T F Meert, F Awouter. Central 5-HT2 antagonists: A preclinical evaluation of a therapeutic potential. Acta neuropsychiatrica. vol 2. issue 4. 2016-03-09. PMID:26952556. |
risperidone is an antipsychotic with therapeutic effects on both the positive and negative symptoms of schizophrenia and with a reduced risk of extrapyramidal side-effects. |
2016-03-09 |
2023-08-13 |
Not clear |
| Robin Emsley, Laila Asmal, Bonginkosi Chiliza, Stefan du Plessis, Jonathan Carr, Martin Kidd, Anil K Malhotra, Matthijs Vink, Rene S Kah. Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. Psychiatry research. vol 233. issue 2. 2016-03-07. PMID:26184461. |
twenty-two antipsychotic-naive patients with first-episode schizophrenia received either risperidone long acting injection or flupenthixol decanoate over 13 weeks and were compared by structural mri with 23 matched healthy volunteers at weeks 0, 4 and 13. |
2016-03-07 |
2023-08-13 |
human |
| Jing-Xu Chen, Yun-Ai Su, Qing-Tao Bian, Li-He Wei, Rong-Zhen Zhang, Yan-Hong Liu, Christoph Correll, Jair C Soares, Fu-De Yang, Shao-Li Wang, Xiang-Yang Zhan. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. vol 58. 2016-03-04. PMID:25981348. |
stable subjects 18-45 years old with schizophrenia and hyperprolactinemia (i.e., >24 ng/ml for females and >20 ng/ml for males) were randomly assigned to receive 8 weeks of placebo (n=30) or oral aripiprazole 5mg/day (n=30), 10mg/day (n=29), or 20mg/day (n=30) added on to fixed dose risperidone treatment. |
2016-03-04 |
2023-08-13 |
human |
| Xiang-Dong Du, Guang-Ya Zhang, Yong Yang, Zhe Li, Wen Pan, Guang-Zhong Yin, Ri-Xia Dong, Hai-Jun Gai, Gang Ye, Jian-Gong Yang, Ying Yuan, Neng-Rong Pan, Wei-Qin Li, Xiao-Wen Xu, Xing-Shi Che. Follow-up of N400 in the Rehabilitation of First-episode Schizophrenia. Chinese medical journal. vol 128. issue 16. 2016-02-25. PMID:26265616. |
this study was to explore the relationship between n400 changes and risperidone treatment and rehabilitation infirst-episode schizophrenia (fes). |
2016-02-25 |
2023-08-13 |
Not clear |
| Xiaofen Zong, Maolin Hu, Zongchang Li, Hongbao Cao, Ying He, Yanhui Liao, Jun Zhou, Deen Sang, Hongzeng Zhao, Jinsong Tang, Luxian Lv, Xiaogang Che. N-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients. Scientific reports. vol 5. 2016-02-24. PMID:25778460. |
n-acetylaspartate reduction in the medial prefrontal cortex following 8 weeks of risperidone treatment in first-episode drug-naïve schizophrenia patients. |
2016-02-24 |
2023-08-13 |
Not clear |
| Bunta Yoshimura, Ikuta Shinkawa, Akiko Konish. Hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in Japan. Asian journal of psychiatry. vol 14. 2016-02-08. PMID:25736075. |
hospitalization risk in patients with schizophrenia before and after initiation of risperidone long-acting injection in japan. |
2016-02-08 |
2023-08-13 |
Not clear |
| Jimmi Nielsen, Signe O W Jensen, Rasmus B Friis, Jan B Valentin, Christoph U Correl. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophrenia bulletin. vol 41. issue 3. 2016-01-29. PMID:25180312. |
comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. |
2016-01-29 |
2023-08-13 |
Not clear |
| S V Sathish Kumar, Vinod Kumar Sinh. Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Indian journal of psychiatry. vol 57. issue 4. 2016-01-28. PMID:26816428. |
comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. |
2016-01-28 |
2023-08-13 |
Not clear |
| Peter F Buckley, Nina R Schooler, Donald C Goff, John Hsiao, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan J Mendelowitz, Del D Miller, Joanne B Severe, Daniel R Wilson, Donna Ames, Juan Bustillo, Jim Mintz, John M Kan. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophrenia bulletin. vol 41. issue 2. 2016-01-25. PMID:24870446. |
at 8 us academic centers, 305 patients with schizophrenia or schizoaffective disorder were randomly assigned to lai risperidone (lai-r) or physician's choice oral sgas. |
2016-01-25 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Gary Remingto. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction. Evidence-based mental health. vol 18. issue 4. 2016-01-22. PMID:26459470. |
improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine d2/3 receptor occupancy following risperidone and olanzapine dose reduction. |
2016-01-22 |
2023-08-13 |
Not clear |
| Satoko Baba, Takeshi Murai, Tomokazu Nakako, Takeshi Enomoto, Michiko Ono, Isao Shimizu, Kazuhito Iked. The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets. Behavioural brain research. vol 287. 2016-01-19. PMID:25804359. |
these results suggest that tandospirone is a promising candidate for the treatment of cognitive deficits associated with schizophrenia and that adjunctive treatment with tandospirone and blonanserin is more appropriate for cognitive deficits than combination therapy with tandospirone and risperidone or haloperidol. |
2016-01-19 |
2023-08-13 |
Not clear |